About this trial
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021). Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumor rates in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to differentiate radionecrosis versus recurrence. These results need to be consolidated prospectively, with homogeneous samples taken from all patients.
The aim of this study is to describe the evolution over time of plasma levels of pro-oncogenic microRNAs, after surgery for grade 4 glioma, in order to assess whether they can be used to identify false-positive recurrences on MRI (radionecrosis).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Major patient
Grade 4 diffuse glioma
Surgery in the neurosurgery department of Caen University Hospital
Patient affiliated to a social security scheme
Disqualifiers
- Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision).
Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma.
Other non-glial histologies, glioneuronal histology
Minor patients
Trial population
Patient with surgically resected grade 4 glioma
Trial design
Cohort
Prospective
Treatments tested in this trial
Blood sample
Diagnostic testBlood sample
Treatment groups
Trial outcomes
Primary outcomes
Recurrence of glioma on MRI
Aspect of recurrence on MRI
Secondary outcomes
OS
Overall Survival
PFS
Progression free survival
Sponsors and contacts
Click on the lead sponsor to view all of their trials.